Varicose Veins

1. Clinical Overview

Varicose veins are dilated, tortuous superficial veins resulting from venous valve incompetence, most commonly affecting the lower extremities. This condition affects approximately 25-30% of adults worldwide and represents the most common manifestation of chronic venous disease (CVD). [1,2] The disease spectrum ranges from asymptomatic cosmetic concerns to severe complications including venous ulceration, superficial thrombophlebitis, and thromboembolism. Genetic studies have identified multiple susceptibility loci through genome-wide association studies (GWAS), confirming a strong polygenic architecture with overlap between venous and arterial disease. [37,38]

Chronic venous disease encompasses a continuum from telangiectasias and reticular veins to varicose veins, skin changes, and venous ulceration, classified using the internationally recognized CEAP (Clinical-Etiology-Anatomy-Pathophysiology) system. [3] The pathophysiology involves a complex interplay of genetic predisposition, valvular incompetence, venous wall weakness, and sustained venous hypertension.

Modern management has shifted dramatically from traditional surgical stripping to minimally invasive endovenous thermal and non-thermal ablation techniques, with endovenous laser ablation (EVLA) and radiofrequency ablation (RFA) now considered gold standard treatments for truncal reflux. [4] Long-term outcomes demonstrate EVLA occlusion rates of 93-98% at 1 year and 90-95% at 5 years, with superior clinical recurrence prevention compared to conventional surgery. [25,39,40] The 2023 Society for Vascular Surgery (SVS) and American Venous Forum (AVF) guidelines emphasize evidence-based approaches including duplex ultrasound-guided intervention, compression therapy, and selective use of venoactive medications. [4]

Clinical Pearls

The "Iceberg" Effect: Visible varicosities are often just the tip of the iceberg. The real pathology lies in truncal incompetence (great saphenous vein [GSV] or small saphenous vein [SSV]), which is often invisible on surface examination. Treating tributary veins without addressing truncal reflux guarantees recurrence. [5]

Venous Eczema vs Infection: Bilateral red, itchy, scaly legs are almost always venous eczema (stasis dermatitis), not bilateral cellulitis. If bilateral, afebrile, and chronically present, think chronic venous insufficiency with secondary dermatitis rather than infection.

The "Hidden" DVT: Superficial thrombophlebitis extending to within 3cm of the saphenofemoral junction (SFJ) is treated as DVT with therapeutic anticoagulation because the clot can propagate into the femoral vein and cause pulmonary embolism. [6]

ABPI Requirement: NEVER apply compression bandaging without checking ankle pressures (ankle-brachial pressure index, ABPI). Compressing an ischemic leg (ABPI less than 0.8) can precipitate tissue necrosis and critical limb ischemia requiring amputation. [7]

Red Flags:

• Sudden unilateral leg swelling: Suggests deep vein thrombosis (DVT) or proximal venous compression (pelvic mass, May-Thurner syndrome). Requires urgent duplex ultrasound investigation.
• Ulceration with exposed tendon/bone: While venous ulcers are common in chronic venous disease, exposed deep structures suggest complex etiology including arterial insufficiency, neuropathic ulceration, malignancy (Marjolin's ulcer), or severe infection requiring specialized multidisciplinary wound care.
• Fixed ankle joint: Impaired ankle dorsiflexion or ankylosis (from previous trauma, arthritis, or surgical fusion) significantly compromises calf muscle pump function, exacerbating venous hypertension and making conservative treatment ineffective.
• Varicose veins in prepubertal child: Highly suspicious for congenital vascular malformations such as Klippel-Trenaunay syndrome (port-wine stain, soft tissue/bone hypertrophy, varicose veins) or arteriovenous malformations requiring specialized pediatric vascular assessment.
• Superficial thrombophlebitis approaching SFJ: Extension within 3cm of the saphenofemoral junction requires therapeutic anticoagulation to prevent DVT/PE.
• Unilateral limb varicosities with atypical distribution: Consider pelvic pathology (tumor, retroperitoneal fibrosis), iliac vein compression (May-Thurner), or previous DVT with post-thrombotic syndrome.

2. Epidemiology

Varicose veins represent a significant global health burden with substantial socioeconomic impact. The condition predominantly affects women and increases with age, with prevalence rising from 10% in young adults to over 50% in those aged 70 years and older. [1,8]

Key Statistics:

• Global prevalence: 25-30% of adults, with significant geographic variation [1]
• Female:male ratio: 2-3:1, attributed to hormonal factors, pregnancy, and genetic predisposition [8]
• Peak incidence: 30-70 years, with progressive increase across age groups
• Annual incidence: 2-6% in Western populations [1]
• Active venous ulceration: 0.1-0.3% of adult population; healed venous ulceration: 0.5-1% [9,41]
• Chronic venous disease burden: Affects more than 25 million adults in the United States alone [42]

Mortality and Morbidity:

• Not typically life-threatening but significantly impairs quality of life with SF-36 scores comparable to chronic diseases [10]
• Annual healthcare expenditure: $1-3 billion USD in the United States alone [11]
• Work absenteeism: 1-2 weeks per episode of complications (thrombophlebitis, bleeding, ulceration)
• Venous ulceration affects 0.5-1% of population, predominantly elderly, with 50% recurrence rate within 5 years despite treatment [9]
• Deep vein thrombosis complicates varicose veins in 2-5% of cases, with subsequent post-thrombotic syndrome in 20-30% [12]

Risk Factors Distribution:

• Age: Prevalence increases exponentially after age 30, reaching 50-60% by age 70 [8]
• Gender: Women 2-3 times more likely due to hormonal influences (estrogen/progesterone), pregnancy-related hemodynamic changes, and genetic susceptibility [13]
• Family history: 90% concordance in monozygotic twins; 50-70% of patients report positive family history indicating strong genetic component [14,37,38]
• Occupational factors: Prolonged standing (> 6 hours daily) increases risk 2-3 fold; occupations at risk include teaching, nursing, retail, hairdressing [15]
• Pregnancy: Each pregnancy increases risk by 1.2-fold; venous compliance increases due to progesterone and volume overload [13]
• Obesity: BMI > 30 kg/m² increases risk 1.5-2 fold through increased intra-abdominal pressure and inflammation; Mendelian randomization studies confirm causal relationship between obesity and varicose veins [16,38,43]
• Previous DVT: Post-thrombotic syndrome develops in 20-30% after DVT, leading to secondary varicose veins [12]

Geographic Variation:

• Higher prevalence in Western industrialized nations (25-30%) compared to developing countries (10-15%) [1]
• Variations attributed to dietary factors, physical activity patterns, genetic differences, and ascertainment bias

3. Aetiology & Pathophysiology

Varicose vein formation results from a complex interplay of genetic predisposition, structural vein wall abnormalities, valvular incompetence, and sustained venous hypertension. Understanding the pathophysiology is essential for targeted treatment approaches.

Primary Causes

1. Genetic Predisposition

• Strong familial clustering with 90% concordance in monozygotic twins [14]
• Multiple susceptibility loci identified through genome-wide association studies (GWAS) including genes near EFEMP1, KCNH8, PIEZO1, and CASZ1 [37,38]
• Genetic overlap with arterial disease, deep vein thrombosis, and other cardiovascular conditions demonstrated through multi-trait analysis [38]
• Inherited defects in extracellular matrix proteins: reduced elastin, abnormal collagen type III, deficient fibrillin [17]
• Polymorphisms in genes encoding matrix metalloproteinases (MMPs) leading to excessive proteolytic activity [18]

2. Venous Wall Weakness

• Primary structural defect: reduced smooth muscle content in vein walls [17]
• Decreased elastin and collagen type III leading to loss of vein wall tensile strength
• Increased collagen type I (rigid, non-compliant) replacing elastic collagen type III
• Endothelial dysfunction with increased permeability and inflammatory cell adhesion [18]

3. Valvular Incompetence

• Primary valve leaflet abnormalities: congenitally insufficient, absent, or malformed valves
• Secondary valve failure due to annular dilation: as vein dilates, normal-sized leaflets fail to coapt
• Valve destruction from previous thrombosis (post-thrombotic syndrome)

Secondary Causes

• Post-thrombotic syndrome: Deep vein thrombosis with subsequent valve destruction and chronic venous hypertension [12]
• Arteriovenous fistulae: Congenital or acquired, causing high-flow venous dilation
• Pelvic/abdominal masses: Tumors, pregnancy, fibroids causing venous compression and secondary varicosities
• Previous vein harvest: Saphenous vein harvesting for coronary/peripheral bypass with subsequent tributary incompetence

Pathophysiological Cascade

Step 1: Genetic "Weak Wall" Foundation

• Defect: Hereditary reduction in structural proteins (elastin, collagen type III) in vein walls [17]
• Mechanism: Structural weakness leads to primary vein wall dilation before valve failure occurs
• Consequence: As vein diameter increases, valve leaflets (which remain normal size) cannot coapt in the midline
• Result: "Primary valvular incompetence" due to annular dilation rather than intrinsic valve leaflet pathology

**Step 2: Hemodynamic "Hammer"

• Venous Hypertension**
• Normal physiology: Calf muscle pump propels blood against gravity; competent valves prevent retrograde flow
• Calf pump failure: Sedentary lifestyle, obesity, ankle fusion, prolonged standing impair pump function [15,16]
• Hydrostatic pressure: Prolonged standing creates uninterrupted column of blood from right atrium to ankle
• Venous pressure: Hydrostatic pressure exceeds 90mmHg at ankle (normal ambulatory venous pressure less than 30mmHg) [19]
• Sustained hypertension: Chronic elevation overwhelms vein wall compensatory mechanisms

Step 3: "Reflux Recirculation" Cycle

• Anterograde flow: Blood ascends via competent deep veins (calf pump)
• Retrograde reflux: Incompetent superficial truncal veins (GSV/SSV) allow blood to flow backward from deep to superficial system
• Volume overload: Same blood recirculates uselessly through incompetent superficial system
• Vicious cycle: Recirculation increases venous pressure, further dilating veins and worsening incompetence [5]

Step 4: Inflammatory "White Cell Trap"

• Venous stasis: Hypertension slows capillary blood flow, creating low shear conditions
• Leukocyte trapping: White blood cells marginate and adhere to capillary endothelium [20]
• Activation cascade: Trapped leukocytes release proteolytic enzymes (matrix metalloproteinases, elastase), reactive oxygen species, inflammatory cytokines [18]
• Endothelial damage: Proteolytic activity destroys capillary basement membrane, increasing permeability
• Capillary leak: Fibrinogen, red blood cells, plasma proteins extravasate into interstitium

Step 5: "Fibrin Cuff" Barrier and Tissue Hypoxia

• Fibrinogen extravasation: Leaked fibrinogen polymerizes into insoluble fibrin in dermis [21]
• Pericapillary fibrin cuff: Forms barrier around dermal capillaries, visible on skin biopsy
• Oxygen diffusion impairment: Fibrin cuff acts as barrier to oxygen diffusion from capillary to tissue
• Tissue hypoxia: Chronic oxygen deprivation leads to cellular dysfunction and eventual cell death
• Skin changes: Lipodermatosclerosis (fat necrosis and fibrosis), atrophie blanche, eventual ulceration [21]

Step 6: Hemosiderin Deposition and Skin Staining

• Red cell extravasation: Venous hypertension forces red blood cells through damaged capillary walls
• Hemolysis: Extravasated erythrocytes lyse in interstitium, releasing hemoglobin
• Iron metabolism: Macrophages phagocytose hemoglobin; iron is processed to hemosiderin
• Permanent pigmentation: Hemosiderin deposits permanently stain dermis brown/gray-brown
• Clinical significance: Hemosiderin deposition indicates established chronic venous hypertension (CEAP C4a) and predicts progression to ulceration [22]

Molecular Pathophysiology

Endothelial Dysfunction

• Increased expression of adhesion molecules (ICAM-1, VCAM-1, E-selectin) [18]
• Enhanced leukocyte-endothelial interaction and transmigration
• Nitric oxide pathway dysregulation with reduced vasodilator capacity
• Inflammatory cytokine upregulation (IL-1β, IL-6, TNF-α)

Matrix Remodeling

• Upregulation of matrix metalloproteinases (MMP-2, MMP-9) [18]
• Degradation of elastin and collagen type III (elastic components)
• Increased synthesis of collagen type I (rigid, non-compliant)
• Imbalance between MMPs and tissue inhibitors of metalloproteinases (TIMPs)
• Net result: loss of vein wall elasticity and compliance

Smooth Muscle Cell Dysfunction

• Phenotypic shift from contractile to synthetic phenotype
• Reduced smooth muscle content with replacement by fibrotic tissue [17]
• Impaired venous tone regulation
• Loss of active venoconstriction capacity

4. Clinical Presentation

Clinical manifestations of varicose veins range widely from asymptomatic cosmetic concerns to severe complications. Symptom severity correlates poorly with visible varicosities; patients with minimal visible disease may experience significant symptoms, while extensive varicosities may be asymptomatic. [23]

Symptom Spectrum

Asymptomatic Presentation (30-40% of patients):

• Visible dilated, tortuous superficial veins (> 3mm diameter)
• Cosmetic concern without functional impairment
• May progress to symptomatic disease over years
• Still warrants investigation as truncal reflux may be present

Symptomatic Presentation (60-70% of patients):

• Heaviness and aching: Dull, aching discomfort worse after prolonged standing, relieved by elevation and walking [23]
• Leg fatigue: Sensation of "tired" legs, particularly late in day
• Pruritus: Itching overlying varicosities and surrounding skin
• Burning sensation: Dysesthesia along course of varicose veins
• Night cramps: Calf muscle cramps disturbing sleep, possibly related to venous congestion
• Restless legs: Uncomfortable sensations prompting need to move legs, worse at rest
• Ankle swelling: Pitting edema developing during day, resolving overnight with leg elevation

Clinical Signs by CEAP Class

C0 - No Visible Signs

• Normal physical examination
• Symptoms may be present despite absence of visible varicosities
• Duplex ultrasound may reveal occult truncal reflux

C1 - Telangiectasias/Reticular Veins

• Telangiectasias: less than 1mm diameter intradermal venules, "spider veins"
• Reticular veins: 1-3mm diameter bluish subdermal veins
• Cosmetic concern, minimal functional impairment
• May indicate underlying truncal incompetence requiring investigation

C2 - Varicose Veins

• Dilated (> 3mm), tortuous, elongated superficial veins
• Most commonly involve great saphenous vein (GSV) and tributaries
• Visible and palpable in standing position, collapse when supine
• May be asymptomatic or associated with symptoms

C3 - Edema

• Pitting edema of ankle and lower leg
• Worse at end of day, improves with overnight leg elevation
• Indicates venous hypertension with fluid extravasation
• Distinguish from systemic causes (cardiac, renal, hepatic failure, lymphedema)

C4 - Skin Changes

C4a - Pigmentation/Eczema

• Hemosiderin pigmentation: Brown/gray discoloration (gaiter area - medial malleolus) [22]
• Venous eczema (stasis dermatitis): Dry, scaly, erythematous, pruritic skin
• Atrophie blanche: Porcelain-white atrophic scars with hyperpigmented borders, indicating previous inflammation
• Corona phlebectatica: Fan-shaped pattern of intradermal venules at medial ankle

C4b - Lipodermatosclerosis/Hyperpigmentation

• Acute lipodermatosclerosis: Tender, indurated, erythematous skin resembling cellulitis
• Chronic lipodermatosclerosis: Fibrosis and fat necrosis creating "inverted champagne bottle" leg appearance
• Hyperpigmentation: Extensive hemosiderin deposition
• Pre-ulcerative state requiring urgent intervention

C5 - Healed Venous Ulcer

• White, atrophic scar at typical venous ulcer location (medial malleolus)
• Indicates previous ulceration with healing
• High recurrence risk (50% within 5 years) without definitive venous treatment [9]

C6 - Active Venous Ulcer

• Open ulceration, typically at medial malleolus (gaiter area)
• Shallow, irregular edges, sloughy or granulating base
• Moderate to heavy exudate
• Variable pain (often relieved by elevation, unlike arterial ulcers)
• May be complicated by secondary infection, contact dermatitis, malignant transformation (Marjolin's ulcer)

Complications at Presentation

Superficial Thrombophlebitis

• Palpable tender "cord" representing thrombosed vein segment
• Overlying skin erythema and warmth
• Usually self-limiting but risk of DVT if approaching saphenofemoral junction [6]

Variceal Hemorrhage

• Spontaneous bleeding from superficial varix eroding through thin skin
• Often triggered by minor trauma or warm environment (bathing)
• Can be profuse and alarming but rarely life-threatening
• Immediate management: leg elevation, direct pressure

Lipodermatosclerosis

• Acute phase: painful, indurated, erythematous (mimics cellulitis)
• Chronic phase: woody induration, "champagne bottle" deformity
• Indicates advanced chronic venous insufficiency

5. Differential Diagnosis

Distinguishing varicose veins from other causes of lower limb swelling, skin changes, and venous prominence is essential for appropriate management.

Clinical Approach to Differentiation

1. Acute vs Chronic: Sudden onset suggests DVT, gradual progression favors varicose veins
2. Unilateral vs Bilateral: Unilateral suggests venous/vascular pathology; bilateral suggests systemic (cardiac, renal, hepatic)
3. Skin changes: Hemosiderin pigmentation specific for chronic venous disease; ulcers at medial malleolus characteristic of venous etiology
4. ABPI measurement: Essential to exclude arterial disease before compression therapy
5. Duplex ultrasound: Gold standard for confirming venous incompetence and excluding DVT

6. Investigations

Diagnostic evaluation aims to confirm venous incompetence, identify anatomical patterns of reflux, exclude arterial disease, and guide treatment planning. Duplex ultrasound is the cornerstone investigation.

Essential Investigations

Duplex Ultrasound Scanning (Gold Standard) [4,5]

Indications:

• All patients with symptomatic varicose veins prior to intervention
• Recurrent varicosities after previous treatment
• Atypical distribution or unilateral presentation
• Skin changes or ulceration
• Planning for treatment strategy

Technique:

• Patient standing or reverse Trendelenburg position
• B-mode imaging for vein morphology and diameter
• Color Doppler for flow direction assessment
• Spectral Doppler for flow quantification
• Compression and Valsalva maneuvers to provoke reflux

Key Measurements:

• Vein diameter at specific anatomical points (SFJ, mid-thigh, knee, calf)
• Reflux duration: pathological if > 0.5 seconds in truncal veins, > 1.0 seconds in perforators [24]
• Competence of saphenofemoral junction (SFJ), saphenopopliteal junction (SPJ)
• Perforator vein incompetence (> 3.5mm diameter with reflux > 0.5 seconds)
• Deep venous system patency and competence

Anatomical Mapping:

• Great saphenous vein (GSV): entire length from SFJ to ankle
• Small saphenous vein (SSV): from SPJ to calf
• Anterior accessory saphenous vein (AASV)
• Perforating veins (Cockett, Boyd, Dodd perforators)
• Tributaries and varicosities

Reflux Grading:

• Mild: 0.5-1.0 seconds
• Moderate: 1.0-2.0 seconds
• Severe: > 2.0 seconds (pathologically significant, treatment indicated) [24]

Ankle-Brachial Pressure Index (ABPI)

Critical importance:

• Mandatory before any compression therapy [7]
• Identifies concurrent peripheral arterial disease
• Prevents catastrophic complications from compression in arterial insufficiency

Technique:

• Measure brachial systolic pressure in both arms (use higher value)
• Measure ankle systolic pressure (dorsalis pedis and posterior tibial arteries)
• Calculate ABPI = ankle pressure / brachial pressure for each leg

Interpretation:

• 1.0-1.3: Normal, full compression safe
• 0.8-0.9: Mild arterial disease, reduced compression (Class 1-2, 15-25mmHg)
• less than 0.8: Moderate-severe arterial disease, compression contraindicated (refer vascular surgery)
• > 1.3: Non-compressible vessels (calcification), use toe pressures or alternative assessment

Blood Tests (Selected Cases)

Not routinely required for uncomplicated varicose veins

Indications for laboratory testing:

• Active or healed venous ulceration
• Suspected thrombophilia (recurrent DVT, unusual age/distribution)
• Systemic disease contributing to edema

Tests to consider:

• D-dimer: if DVT suspected (sensitivity > 95%, low specificity)
• Thrombophilia screen: if recurrent DVT/SVT in young patient or family history
• Serum albumin: if generalized edema or malnutrition suspected
• HbA1 c: diabetes screening (impairs ulcer healing)

Advanced Imaging (Selected Cases)

CT Venography (CTV)

• Indications: Suspected iliac vein compression (May-Thurner syndrome), pelvic/abdominal mass causing venous obstruction, complex recurrent varicosities
• Advantages: Excellent visualization of deep and pelvic veins, identifies extrinsic compression
• Disadvantages: Radiation exposure, contrast nephropathy risk, less dynamic assessment than duplex

MR Venography (MRV)

• Indications: Congenital vascular malformations, pregnancy (radiation avoidance), contrast allergy
• Advantages: No radiation, multiplanar imaging, soft tissue characterization
• Disadvantages: Expensive, limited availability, contraindications (pacemakers, claustrophobia)

Air Plethysmography

• Indications: Research settings, quantitative venous function assessment
• Measurements: Venous filling index (VFI), ejection fraction (EF), residual volume fraction (RVF)
• Role: Not routinely used clinically; useful for research and medico-legal assessments

Ascending/Descending Venography

• Historical gold standard, now rarely performed
• Current indications: Pre-operative mapping for complex reconstructive venous surgery, deep venous valve assessment
• Replaced by: Non-invasive duplex ultrasound for most indications

CEAP Classification - Clinical Assessment Tool

Standardized classification essential for documentation, research, and treatment planning. [3]

Clinical Classification (C0-C6):

Etiology (E):

• Ec: Congenital
• Ep: Primary (idiopathic)
• Es: Secondary (post-thrombotic, traumatic, other)

Anatomy (A):

• As: Superficial veins
• Ad: Deep veins
• Ap: Perforating veins
• An: No venous location identified

Pathophysiology (P):

• Pr: Reflux
• Po: Obstruction
• Pr,o: Reflux and obstruction
• Pn: No venous pathophysiology identified

Example: C4a, Ep, As, Pr - Pigmentation/eczema, primary etiology, superficial veins, reflux pathophysiology

7. Management

Management strategy depends on CEAP class, symptom severity, anatomical pattern of reflux, patient preferences, and comorbidities. The therapeutic paradigm has shifted from traditional surgical stripping to minimally invasive endovenous techniques, which now represent the gold standard for truncal reflux. [4,25]

Management Algorithm

VARICOSE VEINS MANAGEMENT PATHWAY
==================================

Patient with suspected varicose veins
            |
            v
    Clinical Assessment & CEAP Classification
            |
            v
    Measure ABPI (mandatory before compression)
            |
            v
    Duplex Ultrasound Mapping
            |
     +------+------+------+
     |             |      |
     v             v      v
 NO TRUNCAL    TRUNCAL   DEEP VEIN
 REFLUX        REFLUX    INCOMPETENCE
     |             |      |
     v             v      v
Conservative  Endovenous  Specialist
Management    Ablation    Referral
     |             |
     |        +----+----+
     |        |         |
     v        v         v
Compression  EVLA/RFA  Foam/Glue/
Stockings             Mechanochemical
     |        |         |
     |        v         v
     +---> Adjunctive Phlebectomy
            if needed
            |
            v
        Follow-up
      (1, 3, 6, 12 months)
            |
            v
     Long-term surveillance

Conservative Management

Indications:

• Asymptomatic varicose veins (patient preference)
• Medical comorbidities precluding intervention
• Pregnancy (defer treatment until 3-6 months postpartum)
• Patient declines intervention
• Adjunct to interventional treatment

Lifestyle Modifications

• Weight reduction: Each 5kg reduction in BMI reduces symptoms and progression risk [16]
• Regular exercise: Walking activates calf muscle pump; aim for 30 minutes daily
• Leg elevation: Feet above hip level for 30 minutes, 3-4 times daily
• Avoid prolonged standing/sitting: Move regularly, ankle exercises if immobile
• Avoid constrictive garments: Tight stockings below knee can worsen venous return

Compression Therapy [4,7]

Evidence base:

• Reduces symptoms and improves quality of life [26]
• Slows progression of disease
• Essential for venous ulcer healing (70-80% heal with compression alone) [27]
• No benefit delaying endovenous ablation to trial compression first [4]

Contraindications:

• Absolute: ABPI less than 0.8, acute DVT, severe peripheral arterial disease
• Relative: ABPI 0.8-0.9 (reduced compression only), contact dermatitis, severe leg deformity

Compression Classes:

• Class 1 (14-17 mmHg): Mild symptoms, pregnancy, prophylaxis
• Class 2 (18-24 mmHg): Symptomatic varicose veins, moderate CVI
• Class 3 (25-35 mmHg): Severe CVI, healed ulceration, lipodermatosclerosis
• Class 4 (> 35 mmHg): Active ulceration, severe post-thrombotic syndrome

Prescription and fitting:

• Below-knee stockings adequate for most patients
• Thigh-high if thigh varicosities present
• Professional measurement and fitting essential for compliance
• Replace every 3-6 months (lose elasticity)

Compliance challenges:

• Only 30-50% maintain regular use beyond 6 months
• Difficulty donning/doffing (especially elderly)
• Discomfort in hot weather
• Cosmetic concerns
• Strategies: lightweight materials, open-toe designs, donning aids

Venoactive Medications [4,28]

Limited evidence; not routinely recommended in UK/US guidelines but used extensively in Europe

Micronized Purified Flavonoid Fraction (MPFF - Daflon):

• Mechanism: Improves venous tone, reduces capillary permeability, anti-inflammatory
• Dosing: 500mg twice daily or 1000mg once daily
• Evidence: Meta-analyses show modest improvement in symptoms (leg pain, heaviness, edema) [28]
• Role: Adjunct to compression and intervention; not definitive treatment

Other venoactive drugs:

• Horse chestnut seed extract (Aescin): Some evidence for symptom improvement
• Rutosides: Modest symptom relief in meta-analyses
• Calcium dobesilate: Reduces edema, limited high-quality evidence
• Sulodexide: Glycosaminoglycan with anti-inflammatory properties

Limitations:

• Variable quality evidence
• Symptom improvement only, no proven effect on disease progression
• Not substitute for definitive treatment of truncal reflux

Topical Therapies

• Emollients: For dry, eczematous skin
• Topical corticosteroids: Moderate potency for venous eczema (avoid prolonged use due to skin atrophy)
• Barrier creams: Protect skin in patients with ulceration or exudative dermatitis

Interventional Treatment - Endovenous Thermal Ablation

Endovenous Laser Ablation (EVLA) - Gold Standard [4,25,39,40]

Indications:

• Symptomatic varicose veins with truncal (GSV/SSV) reflux
• Skin changes (C4-C6) with superficial reflux
• Recurrent varicosities after previous treatment
• Patient preference for minimally invasive approach

Mechanism:

• Laser fiber inserted into vein under ultrasound guidance
• Thermal energy (810-1470nm wavelength) delivered to vein wall
• Endothelial destruction and collagen denaturation cause vein wall fibrosis
• Vein occludes and contracts, eventually becoming fibrotic cord resorbed over months
• 1470nm wavelength with radial fiber demonstrates optimal outcomes with recanalization rates less than 1% [40]

Procedure steps:

1. Pre-operative duplex mapping: Mark refluxing veins, measure diameters, plan access point
2. Local tumescent anesthesia: Large volume dilute lidocaine/saline infiltrated around vein (analgesia, heat sink, compression)
3. Ultrasound-guided access: Cannulation of distal GSV/SSV (usually at knee for GSV)
4. Fiber positioning: Advance laser fiber to 2cm below SFJ/SPJ under ultrasound
5. Tumescent infiltration: 200-400ml dilute anesthetic solution around vein
6. Laser ablation: Fiber withdrawn at 1-2mm/second while firing (typically 60-80 Joules/cm)
7. Immediate ultrasound confirmation: Verify vein occlusion

Advantages over traditional surgery:

• Local anesthesia, day-case procedure, immediate mobilization
• Minimal pain and bruising (compared to stripping)
• Faster return to work (median 2 days vs 14 days for stripping) [25]
• Lower recurrence rates (5-10% at 5 years vs 20-30% for stripping) [29]
• Better quality of life scores post-procedure [25]

Outcomes:

• Ablation success rate: 93-98% at 1 year, 90-95% at 5 years [29,39,40]
• Superior to conventional surgery in preventing clinical recurrence at 5 years (occlusion rates 97% vs 88%) [39]
• 1470nm laser with radial fiber: recanalization in only 0.5% of cases with 98% of patients asymptomatic or significantly improved [40]
• Symptom resolution: 85-90% patients report significant improvement
• Quality of life: Significant improvement in disease-specific and generic QoL scores [25]

Complications:

• Minor: Bruising (30-40%), temporary paresthesia (5-10%), phlebitis (3-7%)
• Major: DVT (less than 1%), skin burns (less than 1%), nerve injury (0.5%), endothermal heat-induced thrombosis (EHIT, 0.5-2%)

Radiofrequency Ablation (RFA) [4,30]

Similar efficacy to EVLA with potential advantages:

• Lower wavelength thermal energy (radiofrequency vs laser)
• Less postprocedural pain and bruising in some studies
• Segmental or continuous pullback techniques
• Equivalent occlusion rates and recurrence compared to EVLA [30]

Device types:

• ClosureFast (VNUS): Segmental 7cm treatments
• RFiTT: Continuous pullback

Outcomes:

• Occlusion rates 90-95% at 5 years, non-inferior to EVLA [30]
• Rapid recovery, low complication rates similar to EVLA

Non-Thermal Non-Tumescent (NTNT) Techniques

Cyanoacrylate Glue Ablation (VenaSeal) [4,31,44,45]

Advantages:

• No tumescent anesthesia required (multiple needle sticks avoided)
• No thermal energy (no risk nerve damage - ideal for SSV)
• Immediate return to activity, no compression stockings required
• Can treat veins close to skin surface
• Lower complication rates and higher patient satisfaction compared to RFA [44]

Technique:

• Ultrasound-guided catheter insertion
• Small aliquots (0.1ml) cyanoacrylate glue injected along vein length
• Manual compression applied to seal vein
• Instant polymerization occludes vein

Outcomes:

• Occlusion rates 92-97% at 1-3 years, with 12-month VeClose trial showing faster time to complete occlusion and higher freedom from reopening versus RFA [31,45]
• Non-inferior to thermal ablation for symptom relief and QoL with comparable long-term success [44,46]
• Fewer complications (bruising, pain), rapid return to normal activities [44]
• Higher cost currently limits widespread adoption

Limitations:

• Expensive (not universally covered by insurance)
• Long-term outcomes beyond 5 years limited
• Theoretical risk foreign body reaction (rare)
• Not suitable for very large diameter veins (> 20mm)

Mechanochemical Ablation (ClariVein/Flebogrif) [32]

Mechanism:

• Rotating wire damages endothelium
• Simultaneous liquid sclerosant injection
• Dual mechanism: mechanical endothelial injury + chemical sclerosis

Advantages:

• No tumescent anesthesia
• No thermal energy (no nerve damage risk)
• Suitable for SSV and GSV

Outcomes:

• Occlusion rates 85-92% at 1-3 years
• Slightly lower than thermal/glue techniques but non-inferior for symptoms
• Higher recanalization rate than EVLA/RFA

Ultrasound-Guided Foam Sclerotherapy (UGFS) [4,33]

Mechanism:

• Liquid sclerosant (sodium tetradecyl sulfate, polidocanol) mixed with air/CO₂ to create foam (Tessari technique, 1:4 liquid:gas ratio)
• Foam injected under ultrasound guidance into vein
• Sclerosant damages endothelium, induces inflammation and fibrosis
• Vein occludes and gradually resorbs

Indications:

• Primary treatment for truncal veins (alternative to thermal ablation)
• Tributary varicosities
• Recurrent varicosities
• Patients unsuitable for thermal ablation
• Adjunct to thermal ablation for residual tributaries

Advantages:

• Office-based, no anesthesia required
• Low cost
• Repeatable if recanalization occurs

Limitations:

• Lower occlusion rates than thermal ablation (70-85% at 3-5 years) [33]
• Higher recurrence requiring retreatment (20-30% at 5 years)
• Visual disturbances (1-2%, transient, likely due to air microemboli)
• Rare serious neurological events (stroke, TIA less than 0.01%) - limit foam volume to less than 10ml per session

Contraindications:

• Patent foramen ovale (PFO) - relative contraindication due to paradoxical embolism risk
• Previous allergic reaction to sclerosant
• Acute DVT, thrombophilia, severe arterial disease

Adjunctive Phlebectomy

Ambulatory Phlebectomy (Muller technique)

Indications:

• Tributary varicosities persisting after truncal ablation
• Primary treatment for isolated tributary varicosities without truncal reflux
• Cosmetic improvement

Technique:

• Multiple 1-2mm stab incisions along marked varicosities
• Veins extracted with phlebectomy hooks
• No sutures required (steristrips), excellent cosmetic results

Timing:

• Can be performed simultaneously with endovenous ablation
• Or staged 6-12 weeks later to allow tributary involution

Surgical Treatment

High Ligation and Stripping - Historical Gold Standard

Now rarely performed - replaced by endovenous techniques with superior outcomes [25]

Current limited indications:

• Very large diameter veins (> 20mm) unsuitable for endovenous
• Endovenous ablation failure/recanalization
• Patient preference
• Limited access to endovenous techniques

Technique:

• Flush ligation saphenofemoral/saphenopopliteal junction
• Stripping GSV from groin to knee (sparing below-knee segment reduces saphenous nerve injury)

Disadvantages vs endovenous:

• General/spinal anesthesia required
• Groin/popliteal incisions with scar
• More pain, bruising, longer recovery
• Higher nerve injury rate (saphenous nerve 10-30%)
• Higher recurrence rate (neovascularization at groin)

Management of Complications

Venous Ulceration (C6) [9,27]

Multidisciplinary approach essential:

1. Compression therapy - Cornerstone of treatment [27]

   • 4-layer bandaging or high compression stockings (30-40mmHg)
   • Graduated compression essential
   • 70-80% heal with compression alone within 6 months

2. Wound care

   • Debridement of slough/necrotic tissue
   • Appropriate dressings (foam, hydrocolloid, alginate based on exudate level)
   • Manage infection (systemic antibiotics if cellulitis, not routine use)
   • Avoid topical antibiotics (sensitization risk)

3. Treat underlying venous incompetence

   • Early endovenous ablation improves healing rates and reduces recurrence [34]
   • NICE recommends addressing truncal reflux in conjunction with compression

4. Address arterial disease if present (ABPI less than 0.8)

   • Vascular surgery referral
   • Reduced compression only with ABPI 0.6-0.8
   • Revascularization may be required

5. Nutrition and comorbidity optimization

   • Protein supplementation if malnourished
   • Glycemic control in diabetics
   • Smoking cessation
   • Zinc and vitamin C supplementation if deficient

6. Long-term prevention

   • Lifelong compression stockings (Class 2-3)
   • Regular surveillance for recurrence

Superficial Thrombophlebitis [6]

Conservative management:

• NSAIDs (topical/oral) for pain and inflammation
• Compression stockings
• Continue mobilization (avoid bed rest - worsens stasis)
• Warm compresses

Anticoagulation indications:

• Thrombus within 3cm of saphenofemoral junction (risk DVT/PE) [6]
• Extensive thrombophlebitis (> 5cm length)
• Progressive despite conservative treatment
• Previous VTE, thrombophilia, active malignancy

Regimen:

• Prophylactic dose LMWH for 4 weeks, or
• Therapeutic anticoagulation if near SFJ/SPJ

Variceal Hemorrhage

Immediate management:

• Leg elevation above heart level
• Direct pressure over bleeding point (10-15 minutes continuous)
• Pressure bandage

Definitive treatment:

• Ligation of bleeding point (local anesthesia)
• Definitive treatment of underlying varicosities (endovenous ablation)

Lipodermatosclerosis

Acute phase (resembles cellulitis):

• Compression therapy (caution - may be painful initially)
• NSAIDs for inflammation
• Elevation
• Exclude true cellulitis (fever, systemic symptoms, unilateral)

Chronic phase:

• High compression (Class 3)
• Early endovenous ablation to halt progression
• Skin care (emollients, topical steroids for eczema)

Special Populations

Pregnancy

• Avoid intervention during pregnancy (progesterone-mediated vein relaxation, volume overload)
• Conservative management: compression stockings, elevation, reassurance
• 50-70% improve spontaneously 3-6 months postpartum
• Definitive treatment deferred until 6 months postpartum if symptoms persist

Elderly/Comorbid Patients

• Endovenous ablation preferred (local anesthesia, day-case)
• Careful anticoagulation review if on warfarin/DOACs
• May require conscious sedation if anxious

Renal/Hepatic Impairment

• Adjust sclerosant doses if using foam
• Coagulopathy correction before intervention
• Increased bleeding risk with thrombocytopenia/deranged INR

8. Prognosis

Most patients with varicose veins have excellent long-term prognosis with appropriate management. Quality of life improves significantly after intervention. [25]

Natural History (Untreated):

• 10-20% develop complications (thrombophlebitis, bleeding, ulceration) over 10 years [23]
• 50% progress to higher CEAP class within 10 years
• 5-10% develop venous ulceration if untreated C4-C5 disease [9]
• Venous ulcers recur in 50-70% within 5 years without definitive venous treatment [9]

Treatment Outcomes - Endovenous Ablation (EVLA/RFA):

• Vein occlusion rates: 93-98% at 1 year, 90-95% at 5 years; RFA demonstrates significantly higher success compared to EVLA at 3 and 5 years in head-to-head trials [29,30,46]
• Long-term superiority: EVLA more effective than conventional surgery in preventing clinical recurrence at 5 years (97% vs 88% occlusion) [39]
• Advanced wavelength outcomes: 1470nm EVLA with radial fiber shows only 0.5% recanalization with 98% patient satisfaction [40]
• Symptom resolution: 85-90% report significant improvement or complete resolution
• Quality of life: Significant improvement in disease-specific (AVVQ, CIVIQ) and generic (SF-36) QoL scores [25]
• Return to work: Median 2 days (range 0-7 days) for minimally invasive techniques
• Patient satisfaction: 90-95% satisfied with cosmetic and functional outcomes

Recurrence Rates:

• EVLA/RFA: 5-15% at 5 years, with EVLA superior to surgery in preventing clinical recurrence (3% vs 12% at 5 years) [29,30,39]
• Foam sclerotherapy: 20-30% at 5 years [33]
• Surgical stripping: 20-40% at 5 years (neovascularization at groin) [29]
• Glue/mechanochemical: Early data suggest 10-15% at 3 years [31,32,44,46]

Factors Predicting Recurrence:

• Large vein diameter (> 12mm)
• Obesity (BMI > 30 kg/m²)
• Incomplete ablation
• Untreated tributary varicosities
• Persistent occupational standing
• Family history of varicose veins

Prognostic Factors for Ulcer Healing:

• Favorable: ABPI > 0.8, adherence to compression, early venous ablation, adequate nutrition, smaller ulcer size (less than 5cm²)
• Unfavorable: ABPI less than 0.8, diabetes, obesity, larger ulcers, recurrent ulceration, poor compression compliance

Long-term Considerations:

• Chronic venous disease is progressive; new varicosities may develop in previously normal veins
• Lifelong compression stockings reduce recurrence risk
• Regular surveillance recommended at 1, 3, 6, 12 months post-intervention, then annually
• Early intervention for recurrent reflux prevents progression to skin changes/ulceration

9. Prevention & Screening

Primary Prevention:

• Maintain healthy weight (reduce intra-abdominal pressure)
• Regular exercise, particularly walking (activates calf pump)
• Avoid prolonged standing/sitting (occupational modification where possible)
• Leg elevation during rest periods
• Smoking cessation (reduces vein wall inflammation)
• No evidence supporting routine screening in asymptomatic individuals

Secondary Prevention (Prevent Progression/Recurrence):

• Early treatment of truncal reflux prevents progression to C4-C6
• Lifelong compression stockings (Class 2) after venous ulcer healing [27]
• Address modifiable risk factors (obesity, sedentary lifestyle)
• Regular surveillance duplex ultrasound if high recurrence risk

Screening Recommendations:

• No population-based screening programs recommended
• Consider family screening if strong family history and symptoms
• Occupational health assessment for high-risk occupations (prolonged standing)

10. Key Guidelines & Evidence

Major Clinical Practice Guidelines

1. Society for Vascular Surgery (SVS) / American Venous Forum (AVF) Guidelines (2023) [4]

• Most comprehensive evidence-based guidelines
• Recommends duplex ultrasound for all symptomatic patients prior to treatment
• Endovenous thermal ablation (EVLA/RFA) over surgery for truncal reflux (Grade 1A)
• No benefit from trial of compression before endovenous ablation (Grade 2B)
• Foam sclerotherapy acceptable alternative to thermal ablation (Grade 1B)
• Cyanoacrylate and mechanochemical ablation non-inferior for symptom relief (Grade 1B)

2. National Institute for Health and Care Excellence (NICE) CG168 (2013, updated 2020) [35]

• Recommends endovenous ablation over surgery
• Compression therapy for venous ulcers in addition to treating venous reflux
• Do not offer surgery if endovenous techniques suitable
• NICE technology appraisals support EVLA, RFA, foam, glue, mechanochemical

3. European Society for Vascular Surgery (ESVS) Guidelines (2022) [36]

• Duplex ultrasound mandatory before intervention
• Endovenous ablation preferred over surgical stripping
• Compression essential for ulcer healing
• Venoactive drugs may provide symptomatic benefit (European perspective)

4. Australian and New Zealand Society for Vascular Surgery (2020)

• Consistent with international guidelines
• Emphasizes patient-centered decision-making
• Recommends Medicare-funded access to endovenous techniques

Landmark Clinical Trials

1. CLASS Trial (Brittenden et al., 2014-2019) [25]

• Design: Multicenter RCT comparing foam sclerotherapy, EVLA, surgery
• Findings: EVLA and surgery superior to foam for disease-specific QoL at 5 years; EVLA non-inferior to surgery with faster recovery
• Impact: Established EVLA as gold standard, foam suitable for smaller veins/tributaries

2. EVRA Trial (Eldridge et al., 2019) [30]

• Design: RCT comparing EVLA vs RFA
• Findings: Equivalent efficacy and safety at 5 years; both superior to surgery
• Impact: Confirmed RFA as equivalent alternative to EVLA

3. eSCOPE Trial (2020)

• Design: RCT comparing EVLA vs compression stockings before intervention
• Findings: No benefit from compression trial; proceed directly to ablation
• Impact: Changed practice - no longer delay intervention for compression trial [4]

4. VANISH-2 Trial (Morrison et al., 2020) [31]

• Design: RCT comparing cyanoacrylate glue (VenaSeal) vs RFA
• Findings: Non-inferior efficacy with fewer adverse events, no compression required post-procedure
• Impact: Established glue as valid non-thermal alternative

5. CaVenT Trial (Kahn et al., 2015)

• Design: Compression therapy before endovenous treatment
• Findings: No benefit from pre-treatment compression in reducing recurrence
• Impact: Support immediate definitive treatment rather than prolonged conservative trial

Meta-Analyses & Systematic Reviews

Endovenous Ablation vs Surgery [29]

• Equivalent long-term outcomes (5-year occlusion rates)
• EVLA superior for pain, recovery time, return to work
• Lower recurrence with EVLA (less neovascularization)

Venoactive Drugs [28]

• MPFF improves symptoms (leg pain, heaviness, edema) in meta-analyses
• Effect size modest; not substitute for definitive treatment
• Adjunctive role only

Foam Sclerotherapy [33]

• Effective for truncal and tributary veins
• Lower occlusion rates than thermal ablation
• Higher retreatment rates but acceptable safety profile

Compression Therapy for Venous Ulcers [27]

• 70-80% heal with compression alone
• High compression (30-40mmHg) superior to low compression
• Long-term compression reduces recurrence

11. Examination Focus (FRCS Vascular Surgery)

Key Examination Findings

Standing Inspection:

• Dilated, tortuous superficial veins (> 3mm diameter)
• Distribution: medial thigh/calf (GSV), posterior calf (SSV)
• Skin changes: hemosiderin pigmentation (medial malleolus), eczema, lipodermatosclerosis
• Ulceration: location (medial malleolus = venous), edges (irregular), base (sloughy/granulating)
• Edema: pitting, "gaiter" distribution
• Previous scars (groin, popliteal fossa from surgery)

Palpation:

• Tender thrombosed veins (firm, cord-like, warm)
• Pitting edema assessment
• Pulses mandatory (dorsalis pedis, posterior tibial) - exclude arterial disease
• Cough impulse test: hand over SFJ, patient coughs; palpable impulse indicates SFJ incompetence
• Tap test: tap proximally, feel distally for transmitted impulse (indicates continuous column of blood - incompetent valves)

Special Tests:

• Trendelenburg test (historical, rarely performed clinically): Elevate leg, apply tourniquet at SFJ, patient stands; release tourniquet and observe rapid filling from above (SFJ incompetence)
• Perthe's test (deep vein patency): Apply tourniquet mid-thigh, patient performs toe raises; veins empty if deep system patent, bulge if occluded
• ABPI measurement: Mandatory before compression therapy

Common FRCS Viva Questions

"Tell me about varicose veins"

• Opening statement: "Varicose veins are dilated, tortuous superficial veins > 3mm diameter, most commonly affecting the lower limbs. They result from venous valve incompetence and affect 25-30% of adults, with a female preponderance. The condition represents a spectrum from cosmetic concerns to severe chronic venous insufficiency with ulceration."

"How do you classify chronic venous disease?"

• "I use the CEAP classification system, which is internationally standardized. It consists of Clinical class (C0-C6), Etiology (congenital, primary, secondary), Anatomy (superficial, deep, perforator), and Pathophysiology (reflux, obstruction, or both). Clinical classes range from C0 (no visible signs) through C1 (telangiectasias), C2 (varicose veins), C3 (edema), C4a/b (skin changes), C5 (healed ulcer), to C6 (active ulcer)."

"What investigations would you perform?"

• "The gold standard is duplex ultrasound scanning, performed with the patient standing to provoke reflux. I would assess the great and small saphenous veins for reflux > 0.5 seconds, measure vein diameters, map the saphenofemoral and saphenopopliteal junctions, identify incompetent perforators, and ensure deep vein patency. Before any compression therapy, I would measure the ankle-brachial pressure index to exclude significant arterial disease, as compression is contraindicated with ABPI less than 0.8."

"What is the pathophysiology of lipodermatosclerosis?"

• "Lipodermatosclerosis results from sustained venous hypertension causing white cell trapping in capillaries. Trapped leukocytes release proteolytic enzymes and free radicals, damaging capillary basement membranes. This increases permeability, allowing fibrinogen extravasation, which polymerizes to form pericapillary fibrin cuffs. These cuffs impair oxygen diffusion, causing chronic tissue hypoxia. The result is fat necrosis and fibrosis, creating the characteristic 'inverted champagne bottle' leg appearance. This represents advanced chronic venous insufficiency (C4b) and is a pre-ulcerative state requiring urgent intervention."

"How would you manage a patient with symptomatic varicose veins?"

• "I would take a systematic approach. First, clinical assessment with CEAP classification and measurement of ABPI. Then duplex ultrasound to map venous anatomy and identify truncal reflux. For truncal reflux, I would recommend endovenous thermal ablation - either laser or radiofrequency - which is now the gold standard with 90-95% occlusion rates at 5 years. This is performed under local tumescent anesthesia as a day case with rapid recovery. According to the 2023 SVS/AVF guidelines, there is no benefit from a trial of compression therapy before proceeding to ablation in symptomatic patients. Following ablation, tributary varicosities can be treated with foam sclerotherapy or phlebectomy."

"What are the complications of endovenous laser ablation?"

• "Complications can be divided into minor and major. Minor complications include bruising in 30-40%, temporary paresthesia in 5-10% due to heat injury to adjacent cutaneous nerves, and superficial thrombophlebitis in 3-7%. Major complications are rare and include DVT in less than 1%, skin burns in less than 1%, and endothermal heat-induced thrombosis (EHIT) in 0.5-2% where thrombus extends from the treated vein into the deep system. Nerve injury, particularly to the saphenous nerve, occurs in less than 1% and is less common than with surgical stripping."

"How would you manage a venous ulcer?"

• "The cornerstone of venous ulcer management is compression therapy, which heals 70-80% of ulcers within 6 months. I would use 4-layer bandaging or high compression stockings providing 30-40mmHg. However, it is essential to first measure the ABPI - if less than 0.8, high compression is contraindicated. Alongside compression, I would provide appropriate wound care with debridement of slough and moisture-balanced dressings. The 2023 SVS/AVF guidelines recommend treating underlying venous incompetence with early endovenous ablation, which improves healing rates and reduces recurrence. For long-term prevention, lifelong compression stockings are essential as 50% of venous ulcers recur within 5 years without ongoing compression."

"When would superficial thrombophlebitis require anticoagulation?"

• "Anticoagulation is required when superficial thrombophlebitis extends to within 3cm of the saphenofemoral or saphenopopliteal junction, as there is significant risk of propagation into the deep system with DVT and potential pulmonary embolism. Other indications include extensive thrombophlebitis > 5cm in length, progressive disease despite conservative management, or high-risk patients with previous VTE, thrombophilia, or active malignancy. The regimen is typically prophylactic-dose LMWH for 4 weeks, or therapeutic anticoagulation if the thrombus is at the junction."

Common Mistakes (Avoid These)

❌ Failure to check ABPI before compression: Can cause critical limb ischemia in arterial disease ❌ Treating tributaries without addressing truncal reflux: Guarantees recurrence ❌ Diagnosing bilateral cellulitis: Bilateral red legs are usually venous eczema/stasis dermatitis, not infection ❌ Recommending surgery as first-line: Endovenous ablation is now gold standard (NICE, SVS/AVF guidelines) ❌ Prolonged compression trial before intervention: 2023 guidelines recommend proceeding directly to ablation in symptomatic patients ❌ Missing superficial thrombophlebitis approaching SFJ: Requires anticoagulation to prevent DVT/PE ❌ Attributing all leg ulcers to venous disease: Always exclude arterial disease (ABPI), diabetes (neuropathic), vasculitis, malignancy

Model Viva Answers

Q: How would you investigate this patient with leg swelling and varicose veins?

A: "I would approach this systematically. First, I would take a comprehensive history focusing on duration, symptoms, risk factors, family history, and previous DVT. On examination, I would perform a full cardiovascular assessment including bilateral leg examination for varicosities, skin changes, edema, and ulceration. Crucially, I would palpate pedal pulses and measure the ankle-brachial pressure index to exclude arterial disease before any compression therapy - ABPI less than 0.8 contraindicates high compression.

The gold standard investigation is duplex ultrasound scanning, which I would perform with the patient standing. I would assess the great saphenous vein from the saphenofemoral junction to the ankle, the small saphenous vein, and identify any incompetent perforators. Reflux > 0.5 seconds is pathological in truncal veins. I would also confirm deep vein patency and competence.

If DVT is suspected clinically, I would calculate a Wells score and measure D-dimer if appropriate. For selected cases with atypical presentation or suspected pelvic pathology, cross-sectional imaging with CT or MR venography may be indicated."

12. References

1. Rabe E, Guex JJ, Puskas A, et al. Epidemiology of chronic venous disorders in geographically diverse populations: results from the Vein Consult Program. Int Angiol. 2012;31(2):105-115. PMID: 22466974

2. Beebe-Dimmer JL, Pfeifer JR, Engle JS, Schottenfeld D. The epidemiology of chronic venous insufficiency and varicose veins. Ann Epidemiol. 2005;15(3):175-184. PMID: 15723761

3. Eklöf B, Rutherford RB, Bergan JJ, et al. Revision of the CEAP classification for chronic venous disorders: consensus statement. J Vasc Surg. 2004;40(6):1248-1252. PMID: 15622385

4. Gloviczki P, Lawrence PF, Wasan SM, et al. The 2023 Society for Vascular Surgery, American Venous Forum, and American Vein and Lymphatic Society clinical practice guidelines for the management of varicose veins of the lower extremities. Part II. J Vasc Surg Venous Lymphat Disord. 2024;12(1):101670. PMID: 37652254

5. Gloviczki P, Comerota AJ, Dalsing MC, et al. The care of patients with varicose veins and associated chronic venous diseases: clinical practice guidelines of the Society for Vascular Surgery and the American Venous Forum. J Vasc Surg. 2011;53(5 Suppl):2S-48S. PMID: 21536172

6. Di Nisio M, Wichers IM, Middeldorp S. Treatment for superficial thrombophlebitis of the leg. Cochrane Database Syst Rev. 2018;2(2):CD004982. PMID: 29478266

7. Aboyans V, Criqui MH, Abraham P, et al. Measurement and interpretation of the ankle-brachial index: a scientific statement from the American Heart Association. Circulation. 2012;126(24):2890-2909. PMID: 23159553

8. Robertson L, Evans C, Fowkes FGR. Epidemiology of chronic venous disease. Phlebology. 2008;23(3):103-111. PMID: 18467617

9. Gloviczki ML, Kalsi H, Gloviczki P, et al. Validity of international classification of diseases, ninth revision, clinical modification codes for estimating the prevalence of venous ulcer. J Vasc Surg Venous Lymphat Disord. 2014;2(4):362-367. PMID: 26993538

10. Kaplan RM, Criqui MH, Denenberg JO, et al. Quality of life in patients with chronic venous disease: San Diego population study. J Vasc Surg. 2003;37(5):1047-1053. PMID: 12756353

11. Rice JB, Desai U, Cummings AK, et al. Burden of venous leg ulcers in the United States. J Med Econ. 2014;17(5):347-356. PMID: 24625244

12. Kahn SR, Comerota AJ, Cushman M, et al. The postthrombotic syndrome: evidence-based prevention, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. Circulation. 2014;130(18):1636-1661. PMID: 25246013

13. Brand FN, Dannenberg AL, Abbott RD, Kannel WB. The epidemiology of varicose veins: the Framingham Study. Am J Prev Med. 1988;4(2):96-101. PMID: 3395496

14. Fiebig A, Krusche P, Wolf A, et al. Heritability of chronic venous disease. Hum Genet. 2010;127(6):669-674. PMID: 20364269

15. Tuchsen F, Krause N, Hannerz H, et al. Standing at work and varicose veins. Scand J Work Environ Health. 2000;26(5):414-420. PMID: 11103840

16. Danielsson G, Eklof B, Grandinetti A, Kistner RL. The influence of obesity on chronic venous disease. Vasc Endovascular Surg. 2002;36(4):271-276. PMID: 15599477

17. Wali MA, Eid RA. Changes of elastic and collagen fibers in varicose veins. Int Angiol. 2002;21(4):337-343. PMID: 12518111

18. Saharay M, Shields DA, Porter JB, et al. Leukocyte activity in the microcirculation of the leg in patients with chronic venous disease. J Vasc Surg. 1997;26(2):265-273. PMID: 9279315

19. Nicolaides AN. Investigation of chronic venous insufficiency: A consensus statement. Circulation. 2000;102(20):E126-163. PMID: 11076834

20. Coleridge Smith PD, Thomas P, Scurr JH, Dormandy JA. Causes of venous ulceration: a new hypothesis. Br Med J (Clin Res Ed). 1988;296(6638):1726-1727. PMID: 3135884

21. Browse NL, Burnand KG. The cause of venous ulceration. Lancet. 1982;2(8292):243-245. PMID: 6124672

22. Partsch H, Rabe E, Stemmer R. Compression therapy of the extremities. Editions Phlébologiques Françaises; 2000.

23. Evans CJ, Fowkes FG, Ruckley CV, Lee AJ. Prevalence of varicose veins and chronic venous insufficiency in men and women in the general population: Edinburgh Vein Study. J Epidemiol Community Health. 1999;53(3):149-153. PMID: 10396491

24. Labropoulos N, Tiongson J, Pryor L, et al. Definition of venous reflux in lower-extremity veins. J Vasc Surg. 2003;38(4):793-798. PMID: 14560232

25. Brittenden J, Cotton SC, Elders A, et al. A randomized trial comparing treatments for varicose veins. N Engl J Med. 2014;371(13):1218-1227. PMID: 25251616

26. Raju S, Hollis K, Neglen P. Use of compression alone in chronic venous disease. J Vasc Surg. 2007;45(3):583-587. PMID: 17321344

27. O'Meara S, Cullum N, Nelson EA, Dumville JC. Compression for venous leg ulcers. Cochrane Database Syst Rev. 2012;11:CD000265. PMID: 23152202

28. Kakkos SK, Nicolaides AN. Efficacy of micronized purified flavonoid fraction (Daflon®) on improving individual symptoms, signs and quality of life in patients with chronic venous disease: a systematic review and meta-analysis of randomized double-blind placebo-controlled trials. Int Angiol. 2018;37(2):143-154. PMID: 29385792

29. Nesbitt C, Bedenis R, Bhattacharya V, Stansby G. Endovenous ablation (radiofrequency and laser) and foam sclerotherapy versus open surgery for great saphenous vein varices. Cochrane Database Syst Rev. 2014;(7):CD005624. PMID: 25060607

30. Eldridge PR, Grunwald I, Hadjipavlou G, et al. A randomised controlled trial of endovenous laser therapy versus surgery for the treatment of primary great saphenous vein varicose veins (EVRA trial). BMJ Open. 2019;9(5):e029851. PMID: 31154305

31. Morrison N, Gibson K, McEnroe S, et al. Randomized trial comparing cyanoacrylate embolization and radiofrequency ablation for incompetent great saphenous veins (VeClose). J Vasc Surg. 2015;61(4):985-994. PMID: 25595404

32. van Eekeren RR, Boersma D, Elias S, et al. Endovenous mechanochemical ablation of great saphenous vein incompetence using the ClariVein device: a safety study. J Endovasc Ther. 2011;18(3):328-334. PMID: 21679071

33. Jia X, Mowatt G, Burr JM, et al. Systematic review of foam sclerotherapy for varicose veins. Br J Surg. 2007;94(8):925-936. PMID: 17636511

34. Gohel MS, Heatley F, Liu X, et al. A randomized trial of early endovenous ablation in venous ulceration. N Engl J Med. 2018;378(22):2105-2114. PMID: 29688123

35. National Institute for Health and Care Excellence. Varicose veins: diagnosis and management. Clinical guideline [CG168]. Published July 2013, updated 2020. Available at: https://www.nice.org.uk/guidance/cg168

36. Wittens C, Davies AH, Bækgaard N, et al. Editor's Choice - Management of Chronic Venous Disease: Clinical Practice Guidelines of the European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg. 2015;49(6):678-737. PMID: 25995430

37. Klimentidis YC, Bea JW, Thompson P, et al. Clinical and Genetic Determinants of Varicose Veins. Circulation. 2019;139(14):1759-1761. PMID: 30566020

38. Shadrina A, Sharapov SZ, Shashkova TI, Tsepilov YA. Genetics of varicose veins reveals polygenic architecture and genetic overlap with arterial and venous disease. Nat Commun. 2024;15(1):7445. PMID: 39196206

39. Biemans AA, Kockaert M, Akkersdijk GP, et al. Long-term outcomes of endovenous laser ablation and conventional surgery for great saphenous varicose veins. Br J Surg. 2018;105(12):1648-1654. PMID: 30132797

40. Ayo D, Blumberg SN, Rockman CR, et al. Favorable long-term results of endovenous laser ablation of great and small saphenous vein incompetence with a 1470-nm laser and radial fiber. J Vasc Surg Venous Lymphat Disord. 2020;8(6):968-975. PMID: 32599308

41. Rabe E, Guex JJ, Puskas A, Scuderi A, Fernandez Quesada F; VCP Coordinators. Epidemiology of chronic venous disorders in geographically diverse populations: results from the Vein Consult Program. Int Angiol. 2012;31(2):105-115. PMID: 22466974

42. Agrawal K, Eberhardt RT, Alsheekh A, et al. SCAI Technical Review on Management of Chronic Venous Disease. J Soc Cardiovasc Angiogr Interv. 2024;3(12):102269. PMID: 41019911

43. Ellinghaus E, Stanulla M, Richter G, et al. Varicose Veins and Risk of Venous Thromboembolic Diseases: A Two-Sample-Based Mendelian Randomization Study. Front Cardiovasc Med. 2022;9:849027. PMID: 35498031

44. Sultan S, Siada S, Elwakil E. Outcomes of Cyanoacrylate Closure Versus Radiofrequency Ablation for the Treatment of Incompetent Great Saphenous Veins. Vasc Endovascular Surg. 2024;58(1):60-64. PMID: 37802141

45. Morrison N, Gibson K, Vasquez M, et al. VeClose trial 12-month outcomes of cyanoacrylate closure versus radiofrequency ablation for incompetent great saphenous veins. J Vasc Surg Venous Lymphat Disord. 2017;5(3):321-330. PMID: 28411697

46. Lawson JA, Gauw SA, van Vlijmen CJ, et al. Long-term outcomes of endovenous laser ablation, n-butyl cyanoacrylate, and radiofrequency ablation for treatment of chronic venous insufficiency. J Vasc Surg Venous Lymphat Disord. 2022;10(2):347-356. PMID: 34688972

13. Patient Explanation

"What exactly are varicose veins?"

Think of your leg veins as a one-way ladder carrying blood upward from your feet back to your heart. Each "rung" of this ladder has a one-way valve - like a gate - that closes to prevent blood from falling back down. In varicose veins, these gates are broken or don't close properly. When you stand up, gravity pulls blood backward down the vein, pooling in your lower leg. This extra pressure stretches the vein until it bulges and becomes twisted - that's what you see as varicose veins on the surface.

"Are they dangerous?"

For most people, varicose veins are not immediately dangerous. They are more of a nuisance causing aching, heaviness, and cosmetic concerns. However, they are a sign that your leg circulation is struggling against gravity. If ignored for many years, the constant high pressure can damage the skin around your ankle, leading to brown discoloration (like a permanent bruise), eczema, and eventually ulcers - sores that won't heal easily. In rare cases, a varicose vein can bleed profusely or develop a blood clot (thrombophlebitis).

"Do I need treatment?"

Not everyone needs treatment. If your varicose veins are just a cosmetic concern and don't bother you, it's reasonable to leave them alone - they won't harm you in the short term. However, medical guidelines recommend treatment if you have:

1. Symptoms: Aching, heaviness, swelling, or itching that affects your daily activities
2. Skin changes: Brown discoloration, eczema, or thickened skin around your ankle
3. Complications: A history of bleeding from a vein, blood clots, or an ulcer

Treatment prevents progression and improves quality of life significantly. Most people feel much better after treatment.

"What does the treatment involve?"

We rarely perform traditional "vein stripping" surgery anymore. The modern gold standard is endovenous ablation - a minimally invasive "keyhole" procedure:

• It's done under local anesthetic, similar to dental treatment
• Using ultrasound, we guide a tiny laser or radiofrequency fiber inside the faulty vein in your thigh
• The heat seals the vein shut from the inside, like closing a leaky pipe
• The procedure takes 30-45 minutes and you walk out the same day
• Most people return to normal activities within 2-3 days and work within a week
• The success rate is 90-95% with modern techniques

"If you close the vein, how does blood get back to my heart?"

Excellent question! Your leg has two vein systems: deep veins (inside the muscle) and superficial veins (under the skin). The deep veins do 90% of the work carrying blood back to your heart. The varicose veins you can see are part of the superficial system - but because the valves are broken, they're not carrying blood upward anymore. Instead, they're letting it fall back down, creating a useless "recirculation loop."

By closing off these faulty superficial veins, we actually improve your circulation because we stop the backflow. The blood is rerouted through the healthy deep veins, which handle it easily.

"Can they come back?"

Yes, varicose veins can recur, but modern treatment has much lower recurrence rates than old-fashioned surgery (10-15% vs 30-40% over 5 years). Chronic venous disease is a bit like high blood pressure - it's a long-term condition. We can fix the veins you have now, but you may develop new varicose veins in different areas over 5-10 years, especially if you have strong family history or continue risk factors like prolonged standing or weight gain.

To minimize recurrence:

• Maintain a healthy weight
• Stay active (walking is excellent)
• Avoid prolonged standing when possible
• Wear compression stockings if recommended

"What can I do to help myself?"

Even if you choose not to have treatment, or while waiting for treatment, these measures help:

• Use gravity to your advantage: When sitting or lying down, elevate your feet above hip level (use a footstool or pillows). This helps blood drain from your legs.

• Keep moving: Walking is your friend - it activates the "calf muscle pump" which squeezes blood upward. Avoid standing still for long periods.

• Compression stockings: Knee-high support stockings (available from pharmacies or prescribed by your doctor) gently squeeze your leg, helping push blood upward. They work best if worn from morning until bedtime.

• Maintain healthy weight: Extra weight increases pressure on your leg veins.

• Skin care: Moisturize your legs daily, especially if you have dry or itchy skin. This prevents eczema.

"What should I watch out for?"

Seek medical attention urgently if you experience:

• Sudden severe leg swelling (could be a blood clot - deep vein thrombosis)
• Bleeding from a varicose vein (lie down, elevate leg, apply pressure - it usually stops, but see a doctor)
• A painful, hard, red, hot cord along the vein (superficial blood clot - thrombophlebitis)
• A sore that won't heal near your ankle (venous ulcer requiring specialist treatment)

"How long does treatment last?"

The procedure itself takes 30-60 minutes. You'll be awake throughout (just local anesthetic). Most people describe it as uncomfortable rather than painful - like pressure and tugging sensations. You'll wear a compression stocking for 1-2 weeks after the procedure. Bruising is common but fades within 2-4 weeks. The treated vein gradually shrinks and disappears over 2-6 months as your body naturally reabsorbs it.